Human recombinant insulin is a protein-based man-made form of insulin used for the treatment of diabetes. Recombinant insulin is produced through biotechnological processes by inserting human insulin gene into some living organisms like bacteria, yeast to produce high quality insulin in large scale for diabetes treatment. Recombinant insulin products are available in various dosage forms like vials & bottles, premix insulin, and insulin pump/cartridges to improve patient compliance.
Market key trends:
The increasing demand for premix insulin and insulin cartridges is driving the growth of the human recombinant insulin market. Premix insulin, also known as biphasic insulin, combines a quick-acting and intermediate-acting insulin in one injection to mimic the body's natural insulin secretion pattern. Similarly, insulin cartridges deliver exact insulin doses through pumps and provide convenience to users. Their growing popularity among diabetic patients trying to maintain tight control over blood glucose levels is contributing to market growth. Moreover, technological advancements enabling development of novel insulin analogs with faster acting or longer duration of action are expected to bring more product offerings and spur the recombinant insulin market growth over the forecast period.
Segment Analysis
The global human recombinant insulin market is segmented based on product type, application, end user and region. Based on product type, the market is segmented into long acting insulin, rapid acting insulin, premixed insulin and short acting insulin. Among these, long acting insulin segment dominates the market owing to its longer shelf life and effectiveness in maintaining blood glucose levels. Based on application, the market is categorized into type 1 diabetes and type 2 diabetes. The type 1 diabetes segment dominates the market as recombinant insulins are the preferred treatment for type 1 diabetes patients due to their effectiveness in maintaining blood glucose levels.
Key Takeaways
The Global Human Recombinant Insulin Market Growth is expected to witness high growth during the forecast period.
North America region currently dominates the global market owing to high prevalence of diabetes and favorable reimbursement policies for recombinant insulin in countries like US and Canada. The US holds largest market share in North America region. Asia Pacific region is expected to grow at fastest pace during forecast period owing to rising incidence of diabetes due to changes in lifestyle and increasing awareness about treatment. China and India are emerging markets in Asia Pacific region.
Key players operating in the human recombinant insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A. Novo Nordisk A/S dominates the global market owing to its diversified product portfolio and strong brands like NovoRapid and Levemir. Eli Lilly and Company holds second largest market share globally. Sanofi S.A also has significant market presence with its brands like Lantus and Apidra.
For More Details On The Report, Read- https://www.pressreleasebulletin.com/human-recombinant-insulin-market-size/
Comments
0 comment